MACC1 Expression Correlates with PFKFB2 and Survival in Hepatocellular Carcinoma

Ji, Dong; Lu, Zhongxin; Li, Yaoqing; Liang, Zheyong; Zhang, Peng-Fei; Li, Chao; Zhang, Junli; Zheng, Xin; Yao, Yingmin

doi:10.7314/apjcp.2014.15.2.999

Cited by 32 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, an ideal biomarker should be easily accessible and quantifiable, and procedures for measuring a biomarker should be minimally invasive, inexpensive, accurate, and acceptable to both the patient and the physician. While a variety of proteins and other characteristics associated with a type of cancer including DNA methylation, circulating tumor cells, and histone modifications, have attracted the attention of researchers for early diagnosis and prognosis of HCC, the availability of clinically applicable biomarkers remains limited (Liu et al, 2012;Shen et al, 2012;Fu et al, 2013;Ji et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Serum Peroxiredoxin3 is a Useful Biomarker for Early Diagnosis and Assessemnt of Prognosis of Hepatocellular Carcinoma in Chinese Patients

Shi¹,

Wu²,

Yang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Recently, peroxiredoxin3 (PRDX3) was identified as a novel molecular marker for the progression of hepatocellular carcinoma (HCC). However, its potential clinical application as a serum marker for the early diagnosis and prognosis of HCC has not been investigated. Methods: PRDX3, alpha-fetaprotein (AFP), and other biochemical parameters were measured in serum samples from 297 Chinese patients, including 96 with HCC, 98 with liver cirrhosis (LC), and 103 healthy controls (HCs). Correlations between serum PRDX3 expression and clinicopathological variables and the relationship between serum PRDX3 expression and prognosis were analyzed. Results: Serum PRDX3 was significantly higher in HCC patients than in the LC and HC groups. The sensitivity and specificity of serum PRDX3 for the diagnosis of HCC were 85.9% and 75.3%, respectively, at a cutoff of 153.26 ng/mL, and the area under the curve was 0.865. Moreover, serum PRDX3 expression was strongly associated with AFP level, tumor diameter, TNM stage, and portal vein invasion. Kaplan-Meier curve analysis revealed that HCC patients with high serum PRDX3 expression had a shorter median survival time than those with low PRDX3 expression. Moreover, serum PRDX3 expression was an independent risk factor for overall survival. The inverse correlation between serum PRDX3 and patient survival remained significant in patients with early-stage HCC and in those with normal serum AFP levels. Conclusions: Serum PRDX3 can be used as a noninvasive biomarker for the diagnosis and/or prognosis of HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Peroxiredoxin3 is a Useful Biomarker for Early Diagnosis and Assessemnt of Prognosis of Hepatocellular Carcinoma in Chinese Patients

Shi¹,

Wu²,

Yang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Although surgical resection is considered to be the most effective therapeutic method for treatment of patients with primary hepatic carcinoma, the high recurrence rate and early distant metastasis of HCC after surgery remains frustrating (Kobayashi et al, 2006;Tralhao et al, 2007). Identification of factors involved in oncogenesis of HCC may facilitate improvement of early diagnosis and therapeutic approaches (Ji et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

DEP Domain Containing 1 is a Novel Diagnostic Marker and Prognostic Predictor for Hepatocellular Carcinoma

Yuan

Liao²,

Yang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…F2,6BP in turn activates the rate-limiting enzyme of glycolysis: phosphofructokinase-1 (PFK-1). PFKFB2 has been shown to be highly expressed in human liver (18), thyroid (19), and leukemia (20) tumor tissues, and PFKFB has become a molecular target in the development of anti-cancer drugs (21). Future studies will be performed to examine whether UCP2 transported TCA cycle intermediates regulate PFKFB2 expression and/or activity.…”

Section: Resultsmentioning

confidence: 99%

UCP2 Knockout Suppresses Mouse Skin Carcinogenesis

Zhang

Jackson

et al. 2015

Cancer Prevention Research

View full text Add to dashboard Cite

Mitochondrial uncoupling (uncouples electron transport from ATP production) has recently been proposed as a novel survival mechanism for cancer cells, and reduction in free radical generation is the accepted mechanism of action. However, there is no direct evidence supporting that uncoupling proteins promote carcinogenesis. Herein, we examined whether mitochondrial uncoupling affects mouse skin carcinogenesis using uncoupling protein 2 (UCP2) homozygous knockout and wild-type mice. The results indicate that knockout of UCP2 significantly reduced the formation of both benign (papilloma) and malignant (squamous cell carcinoma) tumors. UCP2 knockout did not cause increases in apoptosis during skin carcinogenesis. The rates of oxygen consumption were only decreased in the carcinogen-treated UCP2 knockout mice whereas glycolysis was only increased in the carcinogen-treated wild-type mice. Finally, the levels of metabolites pyruvate, malate and succinate showed different trends after carcinogen treatments between the wild-type and UCP2 knockout mice. Our study is the first to demonstrate that UCP2 knockout suppresses carcinogenesis in vivo. Together with early studies showing that UCP2 is overexpressed in a number of human cancers, UCP2 could be a potential target for cancer prevention and/or therapy.

show abstract

MACC1 Expression Correlates with PFKFB2 and Survival in Hepatocellular Carcinoma

Cited by 32 publications

References 24 publications

Serum Peroxiredoxin3 is a Useful Biomarker for Early Diagnosis and Assessemnt of Prognosis of Hepatocellular Carcinoma in Chinese Patients

Serum Peroxiredoxin3 is a Useful Biomarker for Early Diagnosis and Assessemnt of Prognosis of Hepatocellular Carcinoma in Chinese Patients

DEP Domain Containing 1 is a Novel Diagnostic Marker and Prognostic Predictor for Hepatocellular Carcinoma

UCP2 Knockout Suppresses Mouse Skin Carcinogenesis

Contact Info

Product

Resources

About